Epigallocatechin-3-gallate (EGCG) for clinical trials: more pitfalls than promises?
Epigallocatechin-3-gallate (EGCG), the main and most significant polyphenol in green tea, has shown numerous health promoting effects acting through different pathways, as antioxidant, anti-inflammatory and anti-atherogenic agent, showing gene expression activity, functioning through growth factor-m...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
31 August 2011
|
| In: |
International journal of molecular sciences
Year: 2011, Jahrgang: 12, Heft: 9, Pages: 5592-5603 |
| ISSN: | 1422-0067 |
| DOI: | 10.3390/ijms12095592 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/ijms12095592 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/1422-0067/12/9/5592 
|
| Verfasserangaben: | Derliz Mereles and Werner Hunstein |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1814671552 | ||
| 003 | DE-627 | ||
| 005 | 20230710121828.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220818s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms12095592 |2 doi | |
| 035 | |a (DE-627)1814671552 | ||
| 035 | |a (DE-599)KXP1814671552 | ||
| 035 | |a (OCoLC)1389793198 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Mereles, Derliz |d 1963- |e VerfasserIn |0 (DE-588)129031062 |0 (DE-627)387883754 |0 (DE-576)297456970 |4 aut | |
| 245 | 1 | 0 | |a Epigallocatechin-3-gallate (EGCG) for clinical trials |b more pitfalls than promises? |c Derliz Mereles and Werner Hunstein |
| 246 | 3 | 0 | |a three |
| 264 | 1 | |c 31 August 2011 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 18.08.2022 | ||
| 520 | |a Epigallocatechin-3-gallate (EGCG), the main and most significant polyphenol in green tea, has shown numerous health promoting effects acting through different pathways, as antioxidant, anti-inflammatory and anti-atherogenic agent, showing gene expression activity, functioning through growth factor-mediated pathways, the mitogen-activated protein kinase-dependent pathway, the ubiquitin/proteasome degradation pathway, as well as eliciting an amyloid protein remodeling activity. However, epidemiological inferences are sometimes conflicting and in vitro and in vivo studies may seem discrepant. Current knowledge on how to enhance bioavailability could be the answer to some of these issues. Furthermore, dose levels, administration frequency and potential side effects remain to be examined. | ||
| 650 | 4 | |a bioavailability | |
| 650 | 4 | |a epigallocatechin-3-gallate | |
| 650 | 4 | |a green tea | |
| 700 | 1 | |a Hunstein, Werner |d 1928-2012 |e VerfasserIn |0 (DE-588)1012782662 |0 (DE-627)699775833 |0 (DE-576)345935667 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d Basel : Molecular Diversity Preservation International, 2000 |g 12(2011), 9, Seite 5592-5603 |h Online-Ressource |w (DE-627)316340715 |w (DE-600)2019364-6 |w (DE-576)281194653 |x 1422-0067 |7 nnas |a Epigallocatechin-3-gallate (EGCG) for clinical trials more pitfalls than promises? |
| 773 | 1 | 8 | |g volume:12 |g year:2011 |g number:9 |g pages:5592-5603 |g extent:12 |a Epigallocatechin-3-gallate (EGCG) for clinical trials more pitfalls than promises? |
| 856 | 4 | 0 | |u https://doi.org/10.3390/ijms12095592 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/1422-0067/12/9/5592 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220818 | ||
| 993 | |a Article | ||
| 994 | |a 2011 | ||
| 998 | |g 1012782662 |a Hunstein, Werner |m 1012782662:Hunstein, Werner |d 50000 |e 50000PH1012782662 |k 0/50000/ |p 2 |y j | ||
| 998 | |g 129031062 |a Mereles, Derliz |m 129031062:Mereles, Derliz |d 910000 |d 910100 |e 910000PM129031062 |e 910100PM129031062 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1814671552 |e 4180794241 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"given":"Derliz","role":"aut","family":"Mereles","display":"Mereles, Derliz"},{"role":"aut","family":"Hunstein","display":"Hunstein, Werner","given":"Werner"}],"language":["eng"],"note":["Gesehen am 18.08.2022"],"name":{"displayForm":["Derliz Mereles and Werner Hunstein"]},"origin":[{"dateIssuedKey":"2011","dateIssuedDisp":"31 August 2011"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["1814671552"],"doi":["10.3390/ijms12095592"]},"recId":"1814671552","title":[{"title":"Epigallocatechin-3-gallate (EGCG) for clinical trials","subtitle":"more pitfalls than promises?","title_sort":"Epigallocatechin-3-gallate (EGCG) for clinical trials"}],"physDesc":[{"extent":"12 S."}],"relHost":[{"title":[{"title_sort":"International journal of molecular sciences","title":"International journal of molecular sciences"}],"physDesc":[{"extent":"Online-Ressource"}],"part":{"text":"12(2011), 9, Seite 5592-5603","volume":"12","extent":"12","year":"2011","pages":"5592-5603","issue":"9"},"language":["eng"],"pubHistory":["1.2000 -"],"titleAlt":[{"title":"IJMS"}],"note":["Gesehen am 17.09.20"],"type":{"media":"Online-Ressource","bibl":"periodical"},"id":{"eki":["316340715"],"zdb":["2019364-6"],"issn":["1422-0067","1661-6596"]},"recId":"316340715","origin":[{"dateIssuedDisp":"2000-","dateIssuedKey":"2000","publisherPlace":"Basel","publisher":"Molecular Diversity Preservation International"}],"disp":"Epigallocatechin-3-gallate (EGCG) for clinical trials more pitfalls than promises?International journal of molecular sciences"}]} | ||
| SRT | |a MERELESDEREPIGALLOCA3120 | ||